UCB (EBR:UCB) UCB Media Room: Acquisitions and disposals of own shares
Transparency directive : regulatory news
26/03/2021 20:03
https://mb.cision.com/Public/18595/3315331/8aac312277ab10cc_800x800ar.jpg
** Acquisitions of own shares and disposals of own shares
------------------------------------------------------------
Brussels (Belgium), 26 March 2021 =E2=80=93 20:00 (CET) =E2=80=93 regulated=
information
Acquisitions of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2021.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 750 000 UCB shares on its behalf under the terms of an initial disc=
retionary mandate agreement with validity until 25 June 2021, effective as =
from 8 March 2021, to cover current and future obligations under UCB's Long=
Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2021, UCB repurchased 116=
650 UCB shares on Euronext Brussels in the period from 19 March 2021 up to=
and including 25 March 2021, as follows:=C2=A0
https://mb.cision.com/Public/18595/3315331/98b5d4984012d8d3_800x800ar.png
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members of its personnel, it has disposed of UCB shares =
OTC in view of deliveries of these shares to the relevant members of the pe=
rsonnel, within the framework of the Long Term Incentive Program of the UCB=
Group, as follows:
https://mb.cision.com/Public/18595/3315331/8b7edd972992f085_800x800ar.png
=C2=A0
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .
Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi=
llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
GenericFile
20210326 - UCB Acquisitions and disposals of own shares ENG final (https://=
mb.cision.com/Public/18595/3315331/9356b83e29edbe6d.pdf) GenericFile
20210326 - Verwerving en vervreemding van eigen aandelen NED (https://mb.ci=
sion.com/Public/18595/3315331/9e5ddf534dcb62ee.pdf) GenericFile
20210326 - Rachat et ali=C3=A9nation d actions propres FR (https://mb.cisio=
n.com/Public/18595/3315331/aa9c51ab33ed4975.pdf) Image
Chart 1 March 26 2021 (https://mb.cision.com/Public/18595/3315331/98b5d4984=
012d8d3_org.png) Image
Chart 2 March 26 2021 (https://mb.cision.com/Public/18595/3315331/8b7edd972=
992f085_org.png)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x65179x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=